CliffBio
biologic

Aranesp

darbepoetin alpha

Loss of exclusivityDecember 2015projected — 12-year biologic exclusivity estimate
CompanyAmgen →See this company's full patent-cliff portfolio

Drug detail

Brand nameAranesp
Active ingredientdarbepoetin alpha
Strength200MCG/0.4ML
Dosage formInjection
RouteIntravenous, Subcutaneous
ModalityBiologic
FDA approvalDecember 2003
Marketing statusRx

More from Amgen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Aranesp patent cliff — loss of exclusivity December 2015 | CliffBio